SG Americas Securities
PDLI

SG Americas Securities’s PDL BioPharma, Inc. PDLI Stock Holding History

SG Americas Securities’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,294
Closed -$67K – 3572
2020
Q3 		$67K Sell
21,294
-7,171
-25% -$22.9K ﹤0.01% 2494
2020
Q2 		$83K Sell
28,465
-39,922
-58% -$126K ﹤0.01% 3437
2020
Q1 		$193K Buy
68,387
+43,643
+176% +$141K ﹤0.01% 2533
2019
Q4 		$80K Sell
24,744
-61,314
-71% -$178K ﹤0.01% 2993
2019
Q3 		$186K Buy
86,058
+43,886
+104% +$117K ﹤0.01% 2392
2019
Q2 		$132K Sell
42,172
-58,550
-58% -$190K ﹤0.01% 2667
2019
Q1 		$375K Buy
100,722
+78,371
+351% +$265K ﹤0.01% 2090
2018
Q4 		$65K Buy
22,351
+10,623
+91% +$29.2K ﹤0.01% 2801
2018
Q3 		$31K Sell
11,728
-496,490
-98% -$1.22M ﹤0.01% 3000
2018
Q2 		$1.19M Sell
508,218
-615,397
-55% -$1.72M 0.01% 1294
2018
Q1 		$3.3M Buy
1,123,615
+300,825
+37% +$821K 0.03% 607
2017
Q4 		$2.25M Buy
822,790
+794,318
+2,790% +$2.44M 0.02% 799
2017
Q3 		$97K Buy
+28,472
New +$79.2K ﹤0.01% 3210
2017
Q1 		– Sell
-61,353
Closed -$130K – 3768
2016
Q4 		$130K Buy
61,353
+31,870
+108% +$88.9K ﹤0.01% 2682
2016
Q3 		$99K Buy
+29,483
New +$93.6K ﹤0.01% 3081
2016
Q2 		– Sell
-16,176
Closed -$54K – 3313
2016
Q1 		$54K Sell
16,176
-6,913
-30% -$21.6K ﹤0.01% 2753
2015
Q4 		$82K Sell
23,089
-148,256
-87% -$621K ﹤0.01% 2421
2015
Q3 		$862K Sell
171,345
-234,307
-58% -$1.34M 0.01% 900
2015
Q2 		$2.61M Buy
405,652
+288,347
+246% +$1.93M 0.02% 604
2015
Q1 		$825K Sell
117,305
-270,397
-70% -$1.96M ﹤0.01% 1226
2014
Q4 		$2.99M Buy
387,702
+358,478
+1,227% +$2.84M 0.01% 813
2014
Q3 		$218K Sell
29,224
-989
-3% -$9.18K ﹤0.01% 1948
2014
Q2 		$292K Buy
+30,213
New +$269K ﹤0.01% 1873
2013
Q4 		– Sell
-25,359
Closed -$202K – 3431
2013
Q3 		$202K Buy
25,359
+11,663
+85% +$93.8K ﹤0.01% 2178
2013
Q2 		$106K Buy
+13,696
New +$107K ﹤0.01% 2071

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
Gabelli Funds
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
Winton Group
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Hancock Whitney
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

SG Americas Securities's PDLI Position: Q4 2020 in Review

SG Americas Securities sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 21,294 shares — an estimated $67K sold.

SG Americas Securities first reported a position in PDLI in Q2 2013 and held it in 25 quarters. The position peaked at $3.3M in Q1 2018. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • SG Americas Securities reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • SG Americas Securities sold 21,294 PDL BioPharma, Inc. shares in Q4 2020, an estimated $67K.
  • SG Americas Securities first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 25 quarters.
  • SG Americas Securities's PDL BioPharma, Inc. position peaked at $3.3M in Q1 2018.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on SG Americas Securities's 13F filing for Q4 2020, filed 4 Feb 2021.